Tag: IN.PACT

IN.PACT AV access results show “unrivalled patency” and highly reduced reintervention...

NOTE: This video is ONLY available to watch in selected countries and geographies   Jos van den Berg (Lugano, Switzerland) speaks to Andrew Holden (Auckland, New...

Webinar: Safety of paclitaxel devices—What does the evidence say?

Jos van den Berg (Lugano, Switzerland), Antonio Micari (Bergamo, Italy) and Marianne Brodmann (Graz, Austria) sit down after a specially convened US FDA panel...

Patient-level analysis shows no correlation between paclitaxel and mortality—reactions from LINC

 Renowned experts expressed confidence in the continued use of paclitaxel-coated devices after independent patient-level data presented at LINC 2019 did not show correlation between...
Japanese

Three-year Japanese results show IN.PACT Admiral DCB offers “consistent and durable”...

The IN.PACT Admiral drug-coated balloon (DCB; Medtronic) exhibits a consistent and durable treatment effect in “a more complex patient demographic than typically seen in...

IN.PACT Admiral DCB receives FDA approval for long SFA lesions

Medtronic has announced that it has received US Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon (DCB) to treat long superficial...
Andrew Holden inpact admiral

Andrew Holden: Update on the IN.PACT AV Access trial

Andrew Holden spoke to Vascular News at LINC 2018 (Leipzig Interventional Course; 30 January–2 February, Leipzig, Germany) about the new data from the IN.PACT...

IN.PACT SFA Japan trial shows significantly higher patency compared with PTA...

New two-year results from the IN.PACT SFA Japan trial were presented at the Leipzig Interventional Course (LINC; 30 January–2 February, Leipzig, Germany) by Osamu...

First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...

Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...

LINC 2018 data highlight IN.PACT Admiral as safe and effective treatment...

Medtronic added to its body of clinical evidence supporting the IN.PACT Admiral drug-coated balloon with new presentations that demonstrated durable and consistent clinical outcomes...

First patient enrolled in study of Medtronic IN.PACT arteriovenous access drug-coated...

The first patient has been enrolled in Medtronic’s IN.PACT arteriovenous (AV) access drug-coated balloon (DCB) study for use in patients with end-stage renal disease. The...

Consistent results for Medtronic IN.PACT Admiral in complex peripheral artery disease...

Two new sub-analyses from the IN.PACT Global Study of the IN.PACT Admiral in patients with peripheral artery disease have been reported at the annual...

Medtronic launches European below-the-knee clinical study of drug-coated balloon

Medtronic has launched the IN.PACT BTK study to evaluate the effectiveness of using a drug-coated balloon in patients with below-the-knee (BTK) peripheral artery disease. This...

Results from Asia and Belgium demonstrate consistent results from Medtronic IN.PACT...

New data presented at the 2017 Leipzig Interventional Course (LINC) have demonstrated strong efficacy and consistent outcomes for Medtronic’s IN.PACT Admiral drug-coated balloon across...

REALITY trial enrols first patient in study evaluating Medtronic directional atherectomy...

Medtronic and VIVA Physicians reported on 27 July 2016 the first patient enrolled in the REALITY Study. The VIVA-sponsored study is assessing outcomes for...